Is There A Relationship Between Visfatin Level and Type 2 Diabetes Mellitus In Obese And Non Obese Patients?

被引:8
|
作者
El-Shafey, Eid M. [1 ]
El-Naggar, Gamal F. [1 ]
Al-Bedewy, Mohamed M. [2 ]
El-Sorogy, Hesham [3 ]
机构
[1] Tanta Univ, Fac Med, Internal Med Dept, Neprol Div, Tanta, Egypt
[2] Tanta Univ, Fac Med, Internal Med Dept, Tanta, Egypt
[3] Tanta Univ, Fac Med, Clin Pathol Dept, Tanta, Egypt
关键词
Visfatin; Type 2 diabetes mellitus; Obesity;
D O I
10.4172/2155-6156.S11-001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Visfatin is a newly discovered cytokine that is highly expressed in visceral fat with a direct relationship to type 2 diabetes mellitus (T2DM). The present study was conducted to demonstrate the relationship between plasma visfatin level and T2DM whether in obese or non obese patients. Subjects and methods: This prospective study was carried out on 74 subjects divided into 4 groups. Group I: Twenty obese non diabetic patients, Group II: Twenty obese diabetic patients, Group III: Twenty non obese diabetic patients and Group IV: Fourteen age and gender matched apparently healthy subjects to serve as controls. All patients and controls were subjected to full history taking, complete clinical examination, routine laboratory investigations, fasting serum insulin, homeostasis model assessment of insulin resistance (HOMA IR) and serum visfatin level. Results: Serum visfatin level was significantly increased in the obese subjects and in the diabetics with the highest rise in the obese diabetics suggesting that serum visfatin level has a link between obesity and T2DM. Also, there was a significant positive correlation between serum visfatin level and body mass index (BMI), serum insulin & HOMA IR. Conclusion: There may be a possible role of visfatin in the Pathophysiology of insulin resistance, T2DM and obesity.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] Serum fetuin-A levels in obese and non-obese subjects with and without type 2 diabetes mellitus
    Zhou, Zhong-wei
    Ju, Hui-xiang
    Sun, Ming-zhong
    Chen, Hong-mei
    Fu, Qing-ping
    Jiang, Dong-mei
    CLINICA CHIMICA ACTA, 2018, 476 : 98 - 102
  • [32] Serum testosterone level in obese and Diabetes mellitus Type-II male patients
    Shaikh, Farheen
    Rafiq, Muhammad
    Bhutto, Muhammad Ageel
    Naqvi, Habib
    RAWAL MEDICAL JOURNAL, 2020, 45 (01): : 42 - 45
  • [33] RELATIONSHIP BETWEEN TYPE 2 DIABETES AND PULMONARY FUNCTIONS IN OBESE WOMEN
    Veena, C. N.
    Vastrad, B. C.
    Nandan, T. M.
    JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS, 2015, 4 (12): : 1986 - 1990
  • [34] C-reactive protein as an inflammatory marker in obese and non-obese type 2 diabetes mellitus patients with metabolic syndrome
    Siddiqui, Rabia
    Rukhsana, Nighat
    Jafri, Muhammad Sajid Abbas
    Shakoor, Shazia
    Iqbal, Samreen
    Younas, Muhammad
    RAWAL MEDICAL JOURNAL, 2024, 49 (04):
  • [35] Rosiglitazone is effective in both obese and non-obese patients with type 2 diabetes.
    Cranmer, H
    Jones, NP
    Patwardhan, R
    DIABETOLOGIA, 1999, 42 : A228 - A228
  • [36] Relationship of adiposity to sublclinical atherosclerosis in obese patients with type 2 diabetes
    Hegazi, RAF
    Sutton-Tyrrell, K
    Evans, RW
    Kuller, LH
    Belle, S
    Yamamoto, M
    Edmundowicz, D
    Kelley, DE
    OBESITY RESEARCH, 2003, 11 (12): : 1597 - 1605
  • [37] Relationship between cardiovascular fitness and cardiovascular risk among obese patients with type 2 diabetes
    Dasgupta, K
    Grover, SA
    Lowensteyn, I
    Chan, D
    Rahme, E
    MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2004, 36 (05): : S141 - S141
  • [38] In Japanese Patients With Type 2 Diabetes, Clinical Predictors for Effectiveness of Liraglutide Treatment are Different between Obese and Non-Obese Patients
    Sasaki, Shuji
    Sako, Yasuhiro
    Hirata, Eiichi
    Sakai, Yoshiyuki
    Inoguchi, Toyoshi
    Takayanagi, Ryoichi
    DIABETES, 2012, 61 : A612 - A612
  • [39] Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus
    Maetzel, A
    Rouf, J
    Covington, M
    Wolf, A
    PHARMACOECONOMICS, 2003, 21 (07) : 501 - 512
  • [40] Relationship between cardiovascular fitness and cardiovascular risk among obese patients with type 2 diabetes
    Dasgupta, K
    Grover, S
    Lowensteyn, I
    Rahme, E
    DIABETES, 2004, 53 : A486 - A486